Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37165875)
Watch
English
Getting specific: monoclonal antibodies in multiple sclerosis.
scientific article published on June 2008
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18485317
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 January 2020
review article
1 reference
stated in
Europe PubMed Central
title
Getting specific: monoclonal antibodies in multiple sclerosis
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18485317
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 January 2020
main subject
multiple sclerosis
0 references
antibody
1 reference
based on heuristic
inferred from title
monoclonal antibody
1 reference
based on heuristic
inferred from title
author
Roland Martin
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18485317
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 January 2020
author name string
Andreas Lutterotti
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18485317
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 January 2020
publication date
1 June 2008
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18485317
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 January 2020
published in
Lancet Neurology
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18485317
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 January 2020
volume
7
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18485317
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 January 2020
issue
6
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18485317
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 January 2020
page(s)
538-547
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18485317
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 January 2020
cites work
Continuous cultures of fused cells secreting antibody of predefined specificity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Monoclonal antibody successes in the clinic
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Replacing the complementarity-determining regions in a human antibody with those from a mouse
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Selecting and screening recombinant antibody libraries
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Human antibodies from transgenic animals
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Potent antibody therapeutics by design
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antibody humanization: a case of the 'Emperor's new clothes'?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunogenicity of engineered antibodies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Engineering antibodies for clinical applications
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunology of multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An open trial of OKT3 in patients with multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Depletion of Vbeta5.2/5.3 T cells with a humanized antibody in patients with multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A controlled trial of natalizumab for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
"Thinking without thinking" about natalizumab and PML.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immune surveillance in multiple sclerosis patients treated with natalizumab.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infusion-related hypersensitivity reactions during natalizumab treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
CAMPATH: from concept to clinic
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rituximab: expanding role in therapy for lymphomas and autoimmune diseases
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sites and stages of autoreactive B cell activation and regulation.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The spectrum of neuromyelitis optica
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An open label study of the effects of rituximab in neuromyelitis optica
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibition of Nogo: a key strategy to increase regeneration, plasticity and functional recovery of the lesioned central nervous system
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antibody cocktails: next-generation biopharmaceuticals with improved potency
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1474-4422(08)70110-8
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18485317
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 January 2020
PubMed publication ID
18485317
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18485317
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit